WideCells Group PLC Partners with University of Westminster (8590K)
September 27 2016 - 1:00AM
UK Regulatory
TIDMWDC
RNS Number : 8590K
WideCells Group PLC
27 September 2016
27 September 2016
WideCells Group PLC ('WideCells Group' or 'the Group' or 'the
Company')
Partners with the University of Westminster to Deliver Online
Courses in Stem Cell Technology
WideCells Group PLC, the healthcare services company focused on
collecting and storing stem cells and providing ground breaking
insurance for stem cell treatment, is pleased to announce that its
R&D and training development division, WideAcademy, has
finalised its syllabus of short courses focused on educating
healthcare professionals on the benefits of stem cell storage and
treatment. This will provide the Company with a new revenue stream,
on commencement of the courses.
The ten short courses are currently being developed alongside
the University of Westminster and are anticipated to drive uptake
of the Group's stem cell storage and healthcare services. Jointly
overseen by WideCells Group's Chief Scientific Officer and Dean of
WideAcademy, Dr. Peter Hollands, Dr. Emanuela Volpi, Reader in
Biomedical Science and Dr. John Murphy, Head of Biomedical Science,
both from the University of Westminster, the courses will be
delivered by a team of healthcare professionals with a high level
of expertise in the field. The collaboration between these parties
will ensure the quality of WideAcademy's educational materials as
well academic peer review of course content. The Company
anticipates that the first course will commence in early 2017 with
the launch of the rest to be staggered over the next 24 months.
In conjunction with this, and in line with its strategy to
provide excellence in stem cell education and training, WideAcademy
is in the process of developing a conference programme for
healthcare and medical professionals. WideAcademy will update the
market with further details on the conference, anticipated to be
held in Brazil in 2017, once a programme has been finalised. South
America's cord blood banking services market has experienced
exciting growth in recent years, prompting the Company's decision
to deliver an event in this market.
WideCells Group CEO, João Andrade, said, "Our stated strategy is
to make stem cell treatment affordable and accessible for families
worldwide and in turn to fuel innovation and investment into the
stem cell industry; we believe that the launch of these short
courses will achieve both these goals while also providing the
added commercial benefit of increasing uptake of our storage and
healthcare services. We look forward to opening up registration to
participants.
"Our CSO Peter Hollands has an almost unrivalled knowledge of
stem cell applications and we are proud to have him on our team. He
is passionate about bridging the knowledge gap amongst the
healthcare community regarding the rapid advancements in this
innovative area of medicine and together with the University of
Westminster, a well-respected academic institution, we are ideally
positioned to deliver this. We look forward to providing updates
regarding the course and our conference in the coming months."
**ENDS**
For further information, please visit the Company's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919
033 171
------------------- ------------------------- --------------
Vicarage Capital Broker - Jeremy Woodgate Tel: +44 (0)
Ltd & Rupert Williams 20 3651 2912
------------------- ------------------------- --------------
Shard Capital Broker - Damon Heath Tel: +44 (0)
Partners LLP & Erik Woolgar 207 186 9950
------------------- ------------------------- --------------
St Brides Partners PR - Elisabeth Cowell Tel: +44 (0)
Ltd & Charlotte Heap 20 7236 1177
------------------- ------------------------- --------------
Notes to Editors
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments accessible and
affordable. The Directors believe that the use of cord blood stem
cells for transplant will drive one of the next important phases in
medicine and is therefore developing market leading products in
complementary, strategic areas which are designed to take advantage
of substantial market opportunities in one of the fastest growing
segments in the healthcare industry. With this in mind, it has
created three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process
-- WideCells: a portfolio of best in class stem cell processing
and cord blood storage facilities with an existing presence in UK
and Brazil
-- WideAcademy: developing an education and training division to
promote awareness of the benefits of stem cell storage across the
global general practice community.
The Group has built an experienced senior management team that
has been integral to the development of its growth and business to
date.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families due to it
being simple, safe and painless to collect relative to other
sources of stem cells such as bone marrow - WideCells will focus on
promoting the collection and storage of this.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells
-- 82 illnesses can currently be treated using stem cell procedures
-- Despite initial storage often costing no more than a few
GBPthousand, actual treatment can cost in the GBPhundreds of
thousands
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014
(MAR).
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUBWBUPQGAQ
(END) Dow Jones Newswires
September 27, 2016 02:00 ET (06:00 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Apr 2023 to Apr 2024